Acrivon Therapeutics (ACRV) CDO Erick Gamelin Sells 400 Shares

What Happened

• Erick Gamelin, Chief Development Officer of Acrivon Therapeutics (ACRV), sold 400 shares in an open-market/private sale on August 18, 2026.
• Price was $2.01 per share for a total proceeds of $804. The sale was made automatically to satisfy mandatory tax withholding on vested restricted stock units (RSUs), per the filing footnote.

Key Details

• Transaction date: 2026-08-18; Price: $2.01 per share; Shares sold: 400; Total value: $804.
• Transaction type/code: Sale (S). Footnote F1: shares sold automatically to satisfy mandatory tax withholding on RSU vesting.
• Shares owned after the transaction: not reported in the information provided.
• Filing date/accession: Form filed 2026-08-20 (filed two days after the transaction), which appears timely under the Form 4 two-business-day rule.

Context

• This sale was a tax-withholding disposition tied to RSU vesting rather than an active decision to liquidate a position; such withholding sales are routine and do not necessarily indicate the insider’s view of the company’s prospects.